Medidata Announces Significant Enhancement to myMedidata Suite of Decentralized Clinical Trials (DCTs) Capabilities with Introduction of Video eConsent

Medidata Announces Significant Enhancement to myMedidata Suite of Decentralized Clinical Trials (DCTs) Capabilities with Introduction of Video eConsent

myMedidata Video eConsent Addresses Critical Need for Patient and Site Remote Interaction During the Consent Process

New York, New York -- August 17, 2021 -- Medidata, a Dassault Systèmes company, today announced a significant enhancement of myMedidata eConsent that enables video visits with patients and study staff. With video eConsent, trial participants can engage in remote, face-to-face, live conversation between patients and clinical trial site staff during the informed consent process. Building upon existing eConsent functionality, video eConsent represents yet another step in the revolutionary changes being brought about by decentralized clinical trial (DCT) technology. This expansion of the company’s telemedicine/video visit capability is the most recent addition to the myMedidata portal designed to be a single patient platform for all patient-centered technology.

Medidata eConsent is an innovative, regulatory-compliant, patient-friendly, electronic consent system for clinical trials. Whether onsite or remote, eConsent simplifies the consent learning process for patients, digitizes the enrollment process, and onboards patients directly into Medidata’s industry-leading electronic data capture platform, Rave EDC. With myMedidata eConsent, patients can remotely access the same great eConsent tool through their web-based myMedidata portal. Using video eConsent, the patient consent process is further enhanced with the ability to connect individuals with real-time video to clinical trial staff, boosting knowledge, compliance, and engagement.

The benefits of enabling video interaction during eConsent include:

• Enhanced patient experience by allowing patients to engage with their clinical research team prior to consenting
• Improved consent tracking management, which reduces informed consent errors and eases the administrative burden for sites and study teams
• Accessibility through the myMedidata patient portal so that patients can virtually access all their trial needs in one location with one login.

“The entire Medidata eConsent effort is driven by the need to provide the information patients require to make informed decisions about their healthcare in a convenient setting,” said Anthony Costello, CEO of Patient Cloud at Dassault Systèmes. “With this latest product release, we are replicating the on-site experience in a virtual setting so that patients and caregivers can easily engage openly in critical conversations about the study and consent form before agreeing to join a trial.”

eConsent and myMedidata LIVE are two of the many decentralized clinical trial solutions offered by Medidata. To date, Medidata has applied DCT solutions across more than 44,000 global clinical sites, involving more than 600,000 patients. Nearly 350 sponsors of clinical trials and CROs (contract research organizations) have trusted Medidata to modernize the clinical trial experience and bring better, safer therapies to market faster and more efficiently.

Medidata’s patient-centric tools are built using responsive design principles, as well as input from patient advocates within Medidata’s Patient Insights team, to create an easier and more flexible patient experience. This is particularly relevant during the current COVID-19 pandemic when in-person visits might be limited or restricted.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,700+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata.

 About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systèmes brings value to more than 290,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com.

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.